Compositions and methods targeting complement component 3 for inhibiting tumor growth
AssigneesThe Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
InventorsAviv Regev, Ana Carrizosa Anderson, Ayshwarya Subramanian, Orit Rozenblatt-Rosen
Life of this patent
Estimating the term…
Abstract
This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.
Claims3
An isolated CD8+ T cell genetically modified to decrease the expression of complement receptor CR1 (CD35) and/or CR2 (CD21) wherein the T cell is a tumor infiltrating lymphocyte (TIL) and/or expresses an endogenous T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein said TCR or CAR targets a tumor-specific or tumor-associated antigen.
Dependencies are inferred from the claim text.